Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Trastuzumab Rezetecan in Locally Advanced Malignant Solid Neoplasm: NCT07309770 Clinical Landscape Report 2026
28 September 2026
NCT07309770 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences) in Idiopathic Inflammatory Myopathies: NCT07315087 Clinical Landscape Report 2026
28 September 2026
NCT07315087 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Gemcitabine Hydrochloride in Urothelial Carcinoma of the Urinary Bladder: NCT07322263 Clinical Landscape Report 2026
28 September 2026
NCT07322263 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Gemcitabine Hydrochloride/Docetaxel in Urothelial Carcinoma of the Urinary Bladder: NCT07313891 Clinical Landscape Report 2026
28 September 2026
NCT07313891 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
ACE-1831 in Systemic Lupus Erythematosus: NCT07314567 Clinical Landscape Report 2026
28 September 2026
NCT07314567 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine) in Systemic Lupus Erythematosus: NCT07318259 Clinical Landscape Report 2026
28 September 2026
NCT07318259 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RXIM-002 in Idiopathic Inflammatory Myopathies: NCT07322718 Clinical Landscape Report 2026
28 September 2026
NCT07322718 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
LBL-047 in Systemic Lupus Erythematosus: NCT07323173 Clinical Landscape Report 2026
28 September 2026
NCT07323173 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dapagliflozin in Lupus Nephritis: NCT07323524 Clinical Landscape Report 2026
28 September 2026
NCT07323524 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LUCAR-G79 in Idiopathic Inflammatory Myopathies: NCT07331272 Clinical Landscape Report 2026
28 September 2026
NCT07331272 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Gemcitabine Hydrochloride/Docetaxel in Bladder Cancer: CTRI/2026/01/100721 Clinical Landscape Report 2026
28 September 2026
CTRI/2026/01/100721 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCMA-CD19 cCAR-T cell therapy (iCell Gene Therapeutics) in Lupus Nephritis: NCT07328581 Clinical Landscape Report 2026
28 September 2026
NCT07328581 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.